176 related articles for article (PubMed ID: 20890664)
21. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
22. Effect of bovine GH and ovariectomy on mammary tissue sensitivity to IGF-I in prepubertal heifers.
Purup S; Sejrsen K; Akers RM
J Endocrinol; 1995 Jan; 144(1):153-8. PubMed ID: 7891017
[TBL] [Abstract][Full Text] [Related]
23. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of maternal lactation performance during prolonged lactation in the mouse by mouse GH and long-R3-IGF-I is linked to changes in mammary signaling and gene expression.
Hadsell DL; Parlow AF; Torres D; George J; Olea W
J Endocrinol; 2008 Jul; 198(1):61-70. PubMed ID: 18577570
[TBL] [Abstract][Full Text] [Related]
25. 4-(hydroxyphenyl)retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland.
Green A; Shilkaitis A; Christov K
Carcinogenesis; 1999 Aug; 20(8):1535-40. PubMed ID: 10426803
[TBL] [Abstract][Full Text] [Related]
26. Effects of estradiol and exogenous insulin-like growth factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism.
Wilson ME
J Clin Endocrinol Metab; 1998 Nov; 83(11):4013-21. PubMed ID: 9814485
[TBL] [Abstract][Full Text] [Related]
27. Modulation of brain insulin-like growth factor I (IGF-I) binding sites and hypothalamic GHRH and somatostatin levels by exogenous growth hormone and IGF-I in juvenile rats.
Eshet R; Gil-Ad I; Apelboym O; Segev Y; Phillip M; Werner H
J Mol Neurosci; 2004; 22(3):179-88. PubMed ID: 14997011
[TBL] [Abstract][Full Text] [Related]
28. Craniopharyngioma cell growth is promoted by growth hormone (GH) and is inhibited by tamoxifen: involvement of growth hormone receptor (GHR) and IGF-1 receptor (IGF-1R).
Li Q; You C; Liu L; Rao Z; Sima X; Zhou L; Xu J
J Clin Neurosci; 2013 Jan; 20(1):153-7. PubMed ID: 23117141
[TBL] [Abstract][Full Text] [Related]
29. Paracrine regulation of growth hormone secretion by estrogen in women.
Birzniece V; Sata A; Sutanto S; Ho KK
J Clin Endocrinol Metab; 2010 Aug; 95(8):3771-6. PubMed ID: 20444909
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
31. Neoplastic transformation of mammary epithelial cells in rats is associated with decreased apoptotic cell death.
Shilkaitis A; Green A; Steele V; Lubet R; Kelloff G; Christov K
Carcinogenesis; 2000 Feb; 21(2):227-33. PubMed ID: 10657962
[TBL] [Abstract][Full Text] [Related]
32. Crosstalk between GH/IGF-I axis and steroid hormones (progesterone, 17beta-estradiol) in canine mammary tumours.
Queiroga FL; Pérez-Alenza MD; Silvan G; Peña L; Lopes CS; Illera JC
J Steroid Biochem Mol Biol; 2008 May; 110(1-2):76-82. PubMed ID: 18367392
[TBL] [Abstract][Full Text] [Related]
33. A local increase in the mammary IGF-1: IGFBP-3 ratio mediates the mammogenic effects of estrogen and growth hormone.
Berry SD; McFadden TB; Pearson RE; Akers RM
Domest Anim Endocrinol; 2001 Jul; 21(1):39-53. PubMed ID: 11524173
[TBL] [Abstract][Full Text] [Related]
34. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
35. Suppression of mammary-derived growth inhibitor gene expression by growth hormone and insulin-like growth factor I.
Huynh H; Beamer W
Int J Oncol; 1998 Sep; 13(3):577-82. PubMed ID: 9683796
[TBL] [Abstract][Full Text] [Related]
36. The somatostatin analog octreotide inhibits GH-stimulated, but not IGF-I-stimulated, bone growth in hypophysectomized rats.
Zapf J; Gosteli-Peter M; Weckbecker G; Hunziker EB; Reinecke M
Endocrinology; 2002 Aug; 143(8):2944-52. PubMed ID: 12130560
[TBL] [Abstract][Full Text] [Related]
37. Prepubertal exposure to cow's milk reduces susceptibility to carcinogen-induced mammary tumorigenesis in rats.
Nielsen TS; Khan G; Davis J; Michels KB; Hilakivi-Clarke L
Int J Cancer; 2011 Jan; 128(1):12-20. PubMed ID: 20232392
[TBL] [Abstract][Full Text] [Related]
38. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin.
Tannenbaum GS; Gurd W; Lapointe M; Pollak M
Endocrinology; 1992 Jun; 130(6):3395-401. PubMed ID: 1350760
[TBL] [Abstract][Full Text] [Related]
39. Growth hormone suppresses the expression of IGFBP-5, and promotes the IGF-I-induced phosphorylation of Akt in bovine mammary epithelial cells.
Sakamoto K; Yano T; Kobayashi T; Hagino A; Aso H; Obara Y
Domest Anim Endocrinol; 2007 May; 32(4):260-72. PubMed ID: 16698222
[TBL] [Abstract][Full Text] [Related]
40. The interrelationship between the effects of insulin-like growth factor I and somatostatin on growth hormone secretion by normal rat pituitary cells: the role of glucocorticoids.
Lamberts SW; den Holder F; Hofland LJ
Endocrinology; 1989 Feb; 124(2):905-11. PubMed ID: 2492219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
